[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:msi1-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"MSI1 Gene",92,85,[8,16,22,29,35,41,47,53,60,67,73,80,86,92,98,104,110,117,123,129,135,141,147,153,159,165,171,176,182,187,193,199,205,211,217,223,229,235,241,247,253,259,265,271,277,282,287,293,299,305],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06835387","Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors",[12],"Phase 2","RECRUITING","2026-08-26T02:16:54.044282Z","2026-07-30T01:46:14.415011Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT07270666","ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer",[],"2026-08-26T02:16:20.336282Z","2026-07-19T19:36:05.068430Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT06412198","A Multicenter Phase 1b\u002F2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations",[26],"Phase 1\u002FPhase 2","2026-08-26T02:16:26.411851Z","2026-07-05T05:32:16.754256Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06236139","Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer",[26],"2026-08-26T02:15:45.413021Z","2026-07-05T05:32:16.748678Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06843434","A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma",[12],"2026-08-26T02:15:22.311223Z","2026-07-05T05:32:16.700719Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT07235293","A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.",[12],"2026-08-26T02:17:32.059863Z","2026-07-05T05:32:16.670680Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT07136077","A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy",[12],"2026-08-03T01:00:21.999836Z","2026-07-05T05:32:16.660205Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":58,"content_modified":59},"NCT07500298","Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer",[57],"Phase 1","2026-08-26T02:15:14.574786Z","2026-05-05T02:43:29.541457Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":65,"content_modified":66},"NCT07128355","Botensilimab, Balstilimab, and SBRT in Colorectal Cancer",[64],"Early Phase 1","2026-08-26T02:18:38.077159Z","2026-05-05T02:43:29.536064Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT06300463","Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases",[12],"2026-08-26T02:18:17.007929Z","2026-05-05T02:43:29.409823Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":78,"content_modified":79},"NCT05174169","Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease",[77],"Phase 2\u002FPhase 3","2026-08-26T02:18:26.932189Z","2026-05-05T02:43:29.353861Z",{"nct_id":81,"title":82,"phases":83,"status":13,"updated_at":84,"content_modified":85},"NCT06843551","The Miami \"EMPIRE\" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation",[12],"2026-08-26T02:16:54.876240Z","2026-05-05T02:43:29.351192Z",{"nct_id":87,"title":88,"phases":89,"status":13,"updated_at":90,"content_modified":91},"NCT07411599","Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1\u002F2 Trial (\"Chip-CRC Trial\")",[26],"2026-08-26T02:16:51.982021Z","2026-05-05T02:43:29.339250Z",{"nct_id":93,"title":94,"phases":95,"status":13,"updated_at":96,"content_modified":97},"NCT07321106","A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS\u002FMSI-L Colorectal Cancer",[57],"2026-08-26T02:19:14.560989Z","2026-05-05T02:43:29.335428Z",{"nct_id":99,"title":100,"phases":101,"status":13,"updated_at":102,"content_modified":103},"NCT05672524","A Study of Tucatinib and Trastuzumab in People With Rectal Cancer",[12],"2026-08-26T02:17:00.709807Z","2026-05-05T02:43:29.285490Z",{"nct_id":105,"title":106,"phases":107,"status":13,"updated_at":108,"content_modified":109},"NCT04991948","Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer",[57],"2026-08-26T02:16:22.235886Z","2026-05-05T02:43:29.232449Z",{"nct_id":111,"title":112,"phases":113,"status":13,"updated_at":115,"content_modified":116},"NCT07284849","A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer",[114],"Phase 3","2026-08-26T02:18:18.766496Z","2026-05-05T02:43:29.219129Z",{"nct_id":118,"title":119,"phases":120,"status":13,"updated_at":121,"content_modified":122},"NCT03803553","Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer",[114],"2026-08-26T02:16:24.135291Z","2026-05-05T02:43:29.200175Z",{"nct_id":124,"title":125,"phases":126,"status":13,"updated_at":127,"content_modified":128},"NCT07446322","FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer",[12],"2026-08-26T02:17:33.002248Z","2026-05-05T02:43:29.132436Z",{"nct_id":130,"title":131,"phases":132,"status":13,"updated_at":133,"content_modified":134},"NCT07082439","Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma",[12],"2026-08-26T02:19:30.857183Z","2026-05-05T02:43:28.856382Z",{"nct_id":136,"title":137,"phases":138,"status":13,"updated_at":139,"content_modified":140},"NCT06634875","Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)",[12],"2026-08-26T02:19:08.084946Z","2026-05-05T02:43:28.530208Z",{"nct_id":142,"title":143,"phases":144,"status":13,"updated_at":145,"content_modified":146},"NCT04774419","Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery",[12],"2026-08-26T02:15:48.613507Z","2026-05-05T02:43:28.401063Z",{"nct_id":148,"title":149,"phases":150,"status":13,"updated_at":151,"content_modified":152},"NCT06336902","Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer",[57],"2026-08-26T02:16:55.892527Z","2026-05-05T02:43:28.371310Z",{"nct_id":154,"title":155,"phases":156,"status":13,"updated_at":157,"content_modified":158},"NCT07227636","A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy",[12],"2026-08-26T02:18:49.989941Z","2026-05-05T02:43:28.364702Z",{"nct_id":160,"title":161,"phases":162,"status":13,"updated_at":163,"content_modified":164},"NCT06589440","Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)",[12],"2026-08-26T02:18:56.409949Z","2026-05-05T02:43:28.346454Z",{"nct_id":166,"title":167,"phases":168,"status":13,"updated_at":169,"content_modified":170},"NCT06459869","NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer",[57],"2026-08-26T02:15:03.757872Z","2026-05-05T02:43:28.131496Z",{"nct_id":172,"title":173,"phases":174,"status":13,"updated_at":151,"content_modified":175},"NCT06267729","Study of AZD0754 in Participants With Metastatic Prostate Cancer",[26],"2026-05-05T02:43:28.077996Z",{"nct_id":177,"title":178,"phases":179,"status":13,"updated_at":180,"content_modified":181},"NCT06654037","Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer",[57],"2026-08-26T02:17:34.833510Z","2026-05-05T02:43:28.017987Z",{"nct_id":183,"title":184,"phases":185,"status":13,"updated_at":65,"content_modified":186},"NCT07140679","Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer",[12],"2026-05-05T02:43:27.978396Z",{"nct_id":188,"title":189,"phases":190,"status":13,"updated_at":191,"content_modified":192},"NCT07147231","Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer",[26],"2026-08-26T02:18:46.948970Z","2026-05-05T02:43:27.838424Z",{"nct_id":194,"title":195,"phases":196,"status":13,"updated_at":197,"content_modified":198},"NCT05239546","Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers",[12],"2026-08-26T02:17:18.747857Z","2026-05-05T02:43:27.753684Z",{"nct_id":200,"title":201,"phases":202,"status":13,"updated_at":203,"content_modified":204},"NCT06959550","Phase II Study of Anti-PD-1\u002FVEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer",[12],"2026-08-26T02:18:42.501841Z","2026-05-05T02:43:27.636070Z",{"nct_id":206,"title":207,"phases":208,"status":13,"updated_at":209,"content_modified":210},"NCT07550088","BAL\u002FBOT\u002FagenT-797 in pMMR CRC With Liver Metastases",[12],"2026-08-26T02:16:15.345907Z","2026-05-05T02:43:27.605002Z",{"nct_id":212,"title":213,"phases":214,"status":13,"updated_at":215,"content_modified":216},"NCT04701476","TATE and Pembrolizumab (MK3475) in mCRC and NSCLC",[12],"2026-08-26T02:18:11.042248Z","2026-05-05T02:43:27.512342Z",{"nct_id":218,"title":219,"phases":220,"status":13,"updated_at":221,"content_modified":222},"NCT06369155","Azenosertib in Uterine Serous Carcinoma: Biomarker Study",[12],"2026-08-26T02:17:49.709549Z","2026-05-05T02:43:27.506641Z",{"nct_id":224,"title":225,"phases":226,"status":13,"updated_at":227,"content_modified":228},"NCT07361107","Evaluation of Circulating Immune Response After Histosonics in Colorectal Cancer (ECHO-CRC)",[57],"2026-08-26T02:18:22.309547Z","2026-05-05T02:43:27.484435Z",{"nct_id":230,"title":231,"phases":232,"status":13,"updated_at":233,"content_modified":234},"NCT05855200","Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR\u002FMSI-H Resectable Colon Cancer",[114],"2026-08-26T02:18:13.438956Z","2026-05-05T02:43:27.110176Z",{"nct_id":236,"title":237,"phases":238,"status":13,"updated_at":239,"content_modified":240},"NCT07403721","AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H\u002FdMMR Solid Tumors",[57],"2026-08-26T02:18:17.950264Z","2026-05-05T02:43:26.954091Z",{"nct_id":242,"title":243,"phases":244,"status":13,"updated_at":245,"content_modified":246},"NCT07277322","Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases",[26],"2026-08-26T02:19:15.498463Z","2026-05-05T02:43:26.932462Z",{"nct_id":248,"title":249,"phases":250,"status":13,"updated_at":251,"content_modified":252},"NCT06004245","A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors",[57],"2026-08-26T02:18:14.396999Z","2026-05-05T02:43:26.915489Z",{"nct_id":254,"title":255,"phases":256,"status":13,"updated_at":257,"content_modified":258},"NCT07281768","Capecitabine\u002FOxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer",[12],"2026-08-26T02:16:59.895916Z","2026-05-05T02:43:26.902180Z",{"nct_id":260,"title":261,"phases":262,"status":13,"updated_at":263,"content_modified":264},"NCT07172282","INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases",[64],"2026-08-26T02:17:30.145302Z","2026-05-05T02:43:26.748582Z",{"nct_id":266,"title":267,"phases":268,"status":13,"updated_at":269,"content_modified":270},"NCT07416552","A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)",[57],"2026-08-26T02:17:45.190188Z","2026-05-05T02:35:31.934070Z",{"nct_id":272,"title":273,"phases":274,"status":13,"updated_at":275,"content_modified":276},"NCT06834126","Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial",[57],"2026-08-26T02:18:45.196599Z","2026-05-05T02:35:31.903048Z",{"nct_id":278,"title":279,"phases":280,"status":13,"updated_at":251,"content_modified":281},"NCT06205836","Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer",[12],"2026-05-05T02:35:31.706349Z",{"nct_id":283,"title":284,"phases":285,"status":13,"updated_at":227,"content_modified":286},"NCT05870800","Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER",[12],"2026-05-05T02:35:31.611924Z",{"nct_id":288,"title":289,"phases":290,"status":13,"updated_at":291,"content_modified":292},"NCT07419841","A Phase 1 Study of the Safety and Tolerability of CTX-10726",[57],"2026-08-26T02:18:55.570428Z","2026-07-05T05:32:16.684256Z",{"nct_id":294,"title":295,"phases":296,"status":13,"updated_at":297,"content_modified":298},"NCT05784688","Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors",[26],"2026-08-26T02:18:40.612983Z","2026-05-05T02:43:29.298307Z",{"nct_id":300,"title":301,"phases":302,"status":13,"updated_at":303,"content_modified":304},"NCT02332668","A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051\u002FKEYNOTE-051)",[26],"2026-08-26T02:17:07.954622Z","2026-05-05T02:43:29.025230Z",{"nct_id":306,"title":307,"phases":308,"status":13,"updated_at":309,"content_modified":310},"NCT06203600","Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial",[77],"2026-08-26T02:17:28.381459Z","2026-05-05T02:43:28.966545Z"]